Adjuvant Treatment For Patients With Malignant Peripheral Nerve Sheath TumoursMatthias Kolberg1,2,3 Sigbjørn Smeland2,4 and Ragnhild A Lothe1,2,3,4*
- *Corresponding Author:
- Ragnhild A Lothe
Department of Molecular Oncology
Institute for Cancer Research, Oslo University Hospital
P. O. Box 4950 Nydalen, NO-0424 Oslo, Norway
Tel: +47 2278 1728
E-mail: [email protected]
Received Date: July 28, 2015 Accepted Date: August 25, 2015 Published Date: August 31, 2015
Citation: Kolberg M, Smeland S, Lothe RA (2015) Adjuvant Treatment For Patients With Malignant Peripheral Nerve Sheath Tumours. Chemo Open Access 4:158. doi: 10.4172/2167-7700.1000158
Copyright: © 2015 Kolberg M et al.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited.
In current clinical practice, there are no curative treatment options for the aggressive neuroectodermal cancer malignant peripheral nerve sheath tumor (MPNST) beyond surgical resection . Nearly one half of the patients have neurofibromatosis type 1 (NF1), a cancer predisposition syndrome that increases the risk of MPNST almost 5000 times as compared to the general population, and MPNST patients with NF1 have been reported to have worse prognosis , although the differences in outcome seem to have diminished in recent years. For both NF1 and non-NF1 patients, the 5-year overall survival after MPNST diagnosis is between 30 and 50%.